<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00260</drugbank-id>
  <drugbank-id>APRD00894</drugbank-id>
  <drugbank-id>DB03123</drugbank-id>
  <name>Cycloserine</name>
  <description>Antibiotic substance produced by Streptomyces garyphalus.</description>
  <cas-number>68-41-7</cas-number>
  <unii>95IK5KI84Z</unii>
  <average-mass>102.0919</average-mass>
  <monoisotopic-mass>102.042927446</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Norman P. Jensen, "N-substituted cycloserine compounds, salts thereof, and processes for preparing them." U.S. Patent US3932439, issued December, 1956.</synthesis-reference>
  <indication>Used in combination with up to 5 other drugs as a treatment for Mycobacterium avium complex (MAC) and is also used to treat tuberculosis (TB).</indication>
  <pharmacodynamics>Cycloserine, a broad-spectrum antibiotic, may be bactericidal or bacteriostatic, depending on its concentration at the site of infection and the susceptibility of the organism. Cycloserine works by blocking the formation of these peptidoglycans. By doing this the walls of the bacteria become weak and it results in the death of the bacteria</pharmacodynamics>
  <mechanism-of-action>Cycloserine is an analog of the amino acid D-alanine. It interferes with an early step in bacterial cell wall synthesis in the cytoplasm by competitive inhibition of two enzymes, L-alanine racemase, which forms D-alanine from L-alanine, and D-alanylalanine synthetase, which incorporates D-alanine into the pentapeptide necessary for peptidoglycan formation and bacterial cell wall synthesis.</mechanism-of-action>
  <toxicity>Oral LD&lt;sub&gt;50&lt;/sub&gt; in mouse is 5290 mg/kg, and in rat is over 5000 mg/kg. Symptoms of a cycloserine overdose include drowsiness, confusion, headache, dizziness, irritability, numbness and tingling, difficulty speaking, paralysis, abnormal behavior, seizures, and unconsciousness.</toxicity>
  <metabolism/>
  <absorption>Rapidly and almost completely absorbed (70 to 90%) from the gastrointestinal tract following oral administration.</absorption>
  <half-life>Half-life in patients with normal renal function is 10 hours, and is prolonged in patients with impaired renal function.</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as isoxazolines. These are compounds containing a five-member unsaturated aliphatic ring,  with an oxygen atom adjacent to a nitrogen atoms, and three carbon atoms.</description>
    <direct-parent>Isoxazolines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Azolines</class>
    <subclass>Isoxazolines</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <substituent>Aliphatic heteromonocyclic compound</substituent>
    <substituent>Amine</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Isoxazoline</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">(+)-4-amino-3-isoxazolidinone</synonym>
    <synonym language="english" coder="">(+)-cycloserine</synonym>
    <synonym language="english" coder="">alpha-Cycloserine</synonym>
    <synonym language="spanish" coder="inn">Cicloserina</synonym>
    <synonym language="english" coder="">cyclo-D-Serine</synonym>
    <synonym language="french" coder="inn">Cyclosérine</synonym>
    <synonym language="english" coder="inn">Cycloserine</synonym>
    <synonym language="latin" coder="inn">Cycloserinum</synonym>
    <synonym language="english" coder="">D-(+)-cycloserine</synonym>
    <synonym language="english" coder="">D-4-amino-3-isoxazolidinone</synonym>
    <synonym language="english" coder="">D-4-amino-3-isoxazolidone</synonym>
    <synonym language="english" coder="">D-Cycloserine</synonym>
    <synonym language="english" coder="">DCS</synonym>
    <synonym language="english" coder="">Orientomycin</synonym>
    <synonym language="english" coder="">α-Cycloserine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Cycloserine</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-462</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>250 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cycloserine</name>
      <labeller>Parsolex Gmp Center, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13845-1202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1952-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>250 1/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA060593</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cycloserine</name>
      <labeller>Parsolex Gmp Center, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13845-1201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>250 mg/250mg</strength>
      <route>Oral</route>
      <fda-application-number>ANDA060593</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seromycin</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-0604</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-09-01</started-marketing-on>
      <ended-marketing-on>2010-02-08</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>250 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA060593</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seromycin</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>49349-018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-02</started-marketing-on>
      <ended-marketing-on>2011-08-02</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>250 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA060593</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seromycin</name>
      <labeller>Parsolex Gmp Center, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13845-1200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>250 mg/250mg</strength>
      <route>Oral</route>
      <fda-application-number>ANDA060593</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seromycin</name>
      <labeller>Parsolex Gmp Center, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13845-1203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>250 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA060593</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Seromycin Cap 250mg</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02032414</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-13</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Oxamycin</name>
      <company>Merck</company>
    </international-brand>
    <international-brand>
      <name>Tisomycin</name>
      <company>Lilly</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Seromycin</name>
      <ingredients>Cycloserine</ingredients>
    </mixture>
    <mixture>
      <name>Seromycin</name>
      <ingredients>Cycloserine</ingredients>
    </mixture>
    <mixture>
      <name>Cycloserine</name>
      <ingredients>Cycloserine</ingredients>
    </mixture>
    <mixture>
      <name>Cycloserine</name>
      <ingredients>Cycloserine</ingredients>
    </mixture>
    <mixture>
      <name>Seromycin</name>
      <ingredients>Cycloserine</ingredients>
    </mixture>
    <mixture>
      <name>Cycloserine</name>
      <ingredients>Cycloserine</ingredients>
    </mixture>
    <mixture>
      <name>Seromycin</name>
      <ingredients>Cycloserine</ingredients>
    </mixture>
    <mixture>
      <name>Seromycin Cap 250mg</name>
      <ingredients>Cycloserine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Eli Lilly &amp; Co.</name>
      <url>http://www.lilly.com</url>
    </packager>
    <packager>
      <name>Purdue Pharma LP</name>
      <url>http://www.purduepharma.com</url>
    </packager>
    <packager>
      <name>The Chao Center</name>
      <url>http://www.thechaocenter.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Purdue gmp center llc dba the chao center industrial pharmacy</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Seromycin 250 mg pulvule</description>
      <cost currency="USD">6.0</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Seromycin 250 mg capsule</description>
      <cost currency="USD">7.53</cost>
      <unit>each</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids</category>
      <mesh-id>D000596</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Neutral</category>
      <mesh-id>D021542</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents, Urinary</category>
      <mesh-id>D000892</mesh-id>
    </category>
    <category>
      <category>Antibiotics, Antitubercular</category>
      <mesh-id>D000904</mesh-id>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antimetabolites</category>
      <mesh-id>D000963</mesh-id>
    </category>
    <category>
      <category>Antimycobacterials</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antituberculosis Agents</category>
      <mesh-id>D000995</mesh-id>
    </category>
    <category>
      <category>Drugs for Treatment of Tuberculosis</category>
      <mesh-id/>
    </category>
    <category>
      <category>Isoxazoles</category>
      <mesh-id>D007555</mesh-id>
    </category>
    <category>
      <category>Neurotoxic agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Noxae</category>
      <mesh-id>D009676</mesh-id>
    </category>
    <category>
      <category>Oxazoles</category>
      <mesh-id>D010080</mesh-id>
    </category>
    <category>
      <category>Oxazolidinones</category>
      <mesh-id>D023303</mesh-id>
    </category>
    <category>
      <category>Renal Agents</category>
      <mesh-id>D012076</mesh-id>
    </category>
    <category>
      <category>Toxic Actions</category>
      <mesh-id>D004786</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Enteric bacteria and other eubacteria</affected-organism>
    <affected-organism>Mycobacterium tuberculosis</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>250 1/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>250 mg/250mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>250 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J04AB01">
      <level code="J04AB">Antibiotics</level>
      <level code="J04A">DRUGS FOR TREATMENT OF TUBERCULOSIS</level>
      <level code="J04">ANTIMYCOBACTERIALS</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1pb9</pdb-entry>
    <pdb-entry>1xql</pdb-entry>
  </pdb-entries>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00260.pdf?1265922749</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00609</drugbank-id>
      <name>Ethionamide</name>
      <description>The risk or severity of adverse effects can be increased when Ethionamide is combined with Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The risk or severity of adverse effects can be increased when Isoniazid is combined with Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Ethanol may increase the neurotoxic activities of Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Cycloserine is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The therapeutic efficacy of Lactulose can be decreased when used in combination with Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Cyclosporine may increase the neurotoxic activities of Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Succinylcholine may increase the neurotoxic activities of Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may increase the neurotoxic activities of Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Ziprasidone may increase the neurotoxic activities of Cycloserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Cycloserine may increase the neurotoxic activities of Amitriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Cycloserine may increase the neurotoxic activities of Protriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>Cycloserine may increase the neurotoxic activities of Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Cycloserine may increase the neurotoxic activities of Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Thiethylperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>Cycloserine may increase the neurotoxic activities of Sulpiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>Cycloserine may increase the neurotoxic activities of Loxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>Cycloserine may increase the neurotoxic activities of Remoxipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Prochlorperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>Cycloserine may increase the neurotoxic activities of Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Cycloserine may increase the neurotoxic activities of Droperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Cycloserine may increase the neurotoxic activities of Imipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Cycloserine may increase the neurotoxic activities of Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cycloserine may increase the neurotoxic activities of Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Cycloserine may increase the neurotoxic activities of Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>Cycloserine may increase the neurotoxic activities of Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Cycloserine may increase the neurotoxic activities of Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>Cycloserine may increase the neurotoxic activities of Stavudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>Cycloserine may increase the neurotoxic activities of Moricizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Cycloserine may increase the neurotoxic activities of Trimipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Cycloserine may increase the neurotoxic activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Cycloserine may increase the neurotoxic activities of Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Cycloserine may increase the neurotoxic activities of Didanosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>Cycloserine may increase the neurotoxic activities of Cyclobenzaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Mesoridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Acetophenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>Cycloserine may increase the neurotoxic activities of Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Cycloserine may increase the neurotoxic activities of Doxepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Cycloserine may increase the neurotoxic activities of Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>Cycloserine may increase the neurotoxic activities of Clindamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Cycloserine may increase the neurotoxic activities of Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>Cycloserine may increase the neurotoxic activities of Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Cycloserine may increase the neurotoxic activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>Cycloserine may increase the neurotoxic activities of Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Cycloserine may increase the neurotoxic activities of Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>Cycloserine may increase the neurotoxic activities of Decamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Alimemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Cycloserine may increase the neurotoxic activities of Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>Cycloserine may increase the neurotoxic activities of Bismuth subsalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Cycloserine may increase the neurotoxic activities of Lithium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01598</drugbank-id>
      <name>Imipenem</name>
      <description>Cycloserine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Periciazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>Cycloserine may increase the neurotoxic activities of Molindone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Thioproperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>Cycloserine may increase the neurotoxic activities of Thiothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Cycloserine may increase the neurotoxic activities of Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01627</drugbank-id>
      <name>Lincomycin</name>
      <description>Cycloserine may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Cycloserine may increase the neurotoxic activities of Amineptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>Cycloserine may increase the neurotoxic activities of Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>Cycloserine may increase the neurotoxic activities of Osanetant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>Cycloserine may increase the neurotoxic activities of Bifeprunox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Cycloserine may increase the neurotoxic activities of Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>Cycloserine may increase the neurotoxic activities of Pimavanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>Cycloserine may increase the neurotoxic activities of BL-1020.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>Cycloserine may increase the neurotoxic activities of Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Cycloserine may increase the neurotoxic activities of Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>Cycloserine may increase the neurotoxic activities of Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>Cycloserine may increase the neurotoxic activities of Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>Cycloserine may increase the neurotoxic activities of Perospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>Cycloserine may increase the neurotoxic activities of Amperozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Cycloserine may increase the neurotoxic activities of Dimetacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Cyamemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Cycloserine may increase the neurotoxic activities of Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>Cycloserine may increase the neurotoxic activities of Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>Cycloserine may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Cycloserine may increase the neurotoxic activities of Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Cycloserine may increase the neurotoxic activities of Blonanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Cycloserine may increase the neurotoxic activities of Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>Cycloserine may increase the neurotoxic activities of Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>Cycloserine may increase the neurotoxic activities of RP-5063.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Cycloserine may increase the neurotoxic activities of Methylene blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09275</drugbank-id>
      <name>Bismuth subcitrate potassium</name>
      <description>Cycloserine may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>Cycloserine may increase the neurotoxic activities of Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Cycloserine may increase the neurotoxic activities of Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Cycloserine may increase the neurotoxic activities of Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11281</drugbank-id>
      <name>Bismuth subcarbonate</name>
      <description>Cycloserine may increase the neurotoxic activities of Bismuth subcarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>Cycloserine may increase the neurotoxic activities of Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11537</drugbank-id>
      <name>Pirlimycin</name>
      <description>Cycloserine may increase the neurotoxic activities of Pirlimycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Propiopromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Cycloserine may increase the neurotoxic activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>Cycloserine may increase the neurotoxic activities of Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>Cycloserine may increase the neurotoxic activities of Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>Cycloserine may increase the neurotoxic activities of Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>Cycloserine may increase the neurotoxic activities of Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>Cycloserine may increase the neurotoxic activities of Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Cycloserine may increase the neurotoxic activities of Opipramol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>Cycloserine may increase the neurotoxic activities of Prothipendyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Cycloserine may increase the neurotoxic activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Cycloserine may increase the neurotoxic activities of Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>Cycloserine may increase the neurotoxic activities of Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Butaperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Cycloserine may increase the neurotoxic activities of Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Cycloserine may increase the neurotoxic activities of Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>Cycloserine may increase the neurotoxic activities of Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>Cycloserine may increase the neurotoxic activities of Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Chlorproethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Cycloserine may increase the neurotoxic activities of Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>Cycloserine may increase the neurotoxic activities of Oxypertine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Cycloserine may increase the neurotoxic activities of Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>Cycloserine may increase the neurotoxic activities of Thiazinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Cycloserine may increase the neurotoxic activities of Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>Cycloserine may increase the neurotoxic activities of Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>Cycloserine may increase the neurotoxic activities of Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>Cycloserine may increase the neurotoxic activities of Moperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>Cycloserine may increase the neurotoxic activities of Thiopropazate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Cycloserine may increase the neurotoxic activities of Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Cycloserine may increase the neurotoxic activities of Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>Cycloserine may increase the neurotoxic activities of Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>Cycloserine may increase the neurotoxic activities of Mosapramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Cycloserine may increase the neurotoxic activities of Imipramine oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>Cycloserine may increase the neurotoxic activities of Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>Cycloserine may increase the neurotoxic activities of Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>Cycloserine may increase the neurotoxic activities of Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Cycloserine may increase the neurotoxic activities of Bismuth subgallate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13910</drugbank-id>
      <name>Valproate bismuth</name>
      <description>Cycloserine may increase the neurotoxic activities of Valproate bismuth.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>Cycloserine may increase the neurotoxic activities of Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>Cycloserine may increase the neurotoxic activities of Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00781</drugbank-id>
      <name>Polymyxin B</name>
      <description>Cycloserine may increase the neurotoxic activities of Polymyxin B.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-2.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>0.93</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>8.77e+02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-2.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(4R)-4-amino-1,2-oxazolidin-3-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>cycloserine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>102.0919</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>102.042927446</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>N[C@@H]1CONC1=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C3H6N2O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>DYDCUQKUCUHJBH-UWTATZPHSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>64.35</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>21.85</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>8.87</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>4.21</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.36</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>155.5 dec °C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>8528</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>40009</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>6234</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506865</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C08057</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5998</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50038178</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164764600</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>4AX</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001468</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Cycloserine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL771</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/cycloserine.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000733</id>
      <name>D-alanine--D-alanine ligase A</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A4412</ref-id>
            <pubmed-id>11073937</pubmed-id>
            <citation>Belanger AE, Porter JC, Hatfull GF: Genetic analysis of peptidoglycan biosynthesis in mycobacteria: characterization of a ddlA mutant of Mycobacterium smegmatis. J Bacteriol. 2000 Dec;182(23):6854-6.</citation>
          </article>
          <article>
            <ref-id>A4413</ref-id>
            <pubmed-id>15302885</pubmed-id>
            <citation>Noda M, Kawahara Y, Ichikawa A, Matoba Y, Matsuo H, Lee DG, Kumagai T, Sugiyama M: Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase and D-alanyl-D-alanine ligase, which are target enzymes of D-cycloserine. J Biol Chem. 2004 Oct 29;279(44):46143-52. Epub 2004 Aug 9.</citation>
          </article>
          <article>
            <ref-id>A4414</ref-id>
            <pubmed-id>15948948</pubmed-id>
            <citation>McCoy AJ, Maurelli AT: Characterization of Chlamydia MurC-Ddl, a fusion protein exhibiting D-alanyl-D-alanine ligase activity involved in peptidoglycan synthesis and D-cycloserine sensitivity. Mol Microbiol. 2005 Jul;57(1):41-52.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0A6J8" source="Swiss-Prot">
        <name>D-alanine--D-alanine ligase A</name>
        <general-function>Manganese ion binding</general-function>
        <specific-function>Cell wall formation.</specific-function>
        <gene-name>ddlA</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.81</theoretical-pi>
        <molecular-weight>39315.435</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M58467</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>145722</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0A6J8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DDLA_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>6.3.2.4</synonym>
          <synonym>D-Ala-D-Ala ligase A</synonym>
          <synonym>D-alanylalanine synthetase A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010516|D-alanine--D-alanine ligase A
MEKLRVGIVFGGKSAEHEVSLQSAKNIVDAIDKSRFDVVLLGIDKQGQWHVSDASNYLLN
ADDPAHIALRPSATSLAQVPGKHEHQLIDAQNGQPLPTVDVIFPIVHGTLGEDGSLQGML
RVANLPFVGSDVLASAACMDKDVTKRLLRDAGLNIAPFITLTRANRHNISFAEVESKLGL
PLFVKPANQGSSVGVSKVTSEEQYAIAVDLAFEFDHKVIVEQGIKGREIECAVLGNDNPQ
ASTCGEIVLTSDFYAYDTKYIDEDGAKVVVPAAIAPEINDKIRAIAVQAYQTLGCAGMAR
VDVFLTPENEVVINEINTLPGFTNISMYPKLWQASGLGYTDLITRLIELALERHAADNAL
KTTM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010517|D-alanine--D-alanine ligase A (ddlA)
ATGGAAAAACTGCGGGTAGGAATCGTTTTTGGTGGTAAATCAGCGGAACATGAAGTGTCT
CTGCAATCGGCAAAAAACATTGTCGATGCCATTGATAAAAGTCGCTTCGACGTTGTGCTG
CTGGGCATTGATAAACAAGGGCAATGGCACGTCAGCGATGCCAGCAATTATCTGCTAAAT
GCAGACGATCCTGCCCATATTGCGTTGCGCCCTTCGGCGACCAGCCTTGCGCAGGTGCCA
GGTAAACATGAGCATCAGCTTATCGACGCGCAAAACGGTCAGCCGTTGCCGACGGTGGAT
GTCATTTTCCCGATTGTCCACGGTACGCTGGGCGAAGATGGTTCCTTGCAGGGAATGCTG
CGGGTCGCCAATTTACCGTTTGTAGGTTCTGATGTTCTGGCTTCAGCAGCCTGTATGGAC
AAAGATGTCACCAAACGTCTGCTACGCGATGCCGGGCTGAACATTGCGCCATTTATTACC
CTGACGCGCGCCAATCGTCACAACATTAGTTTTGCCGAAGTGGAGTCTAAACTGGGGTTA
CCACTGTTTGTAAAACCGGCTAATCAGGGCTCTTCTGTTGGTGTCAGCAAAGTAACCAGT
GAAGAACAGTACGCAATTGCCGTCGATCTGGCGTTCGAGTTCGATCATAAAGTGATCGTT
GAGCAAGGGATCAAAGGTCGTGAGATCGAATGCGCAGTTCTGGGCAACGACAATCCGCAA
GCCAGCACCTGTGGAGAGATCGTACTCACCAGCGATTTCTATGCCTACGACACCAAGTAC
ATTGACGAAGATGGCGCGAAAGTGGTAGTTCCGGCAGCCATTGCGCCAGAAATCAACGAT
AAGATCCGGGCGATTGCCGTTCAGGCTTATCAAACGTTGGGATGCGCAGGCATGGCGCGT
GTAGACGTGTTTTTAACCCCAGAGAACGAAGTGGTGATCAACGAGATCAACACCCTGCCT
GGCTTCACTAATATCAGTATGTATCCGAAGCTGTGGCAAGCCAGCGGTCTGGGTTACACC
GATCTGATCACACGTTTGATTGAACTGGCGCTGGAGCGTCACGCTGCGGATAACGCATTG
AAAACCACAATGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07478</identifier>
            <name>Dala_Dala_lig_C</name>
          </pfam>
          <pfam>
            <identifier>PF01820</identifier>
            <name>Dala_Dala_lig_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>D-alanine-D-alanine ligase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>magnesium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>manganese ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000806</id>
      <name>Alanine racemase</name>
      <organism>Mycobacterium avium</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A11261</ref-id>
            <pubmed-id>12499203</pubmed-id>
            <citation>Feng Z, Barletta RG: Roles of Mycobacterium smegmatis D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob Agents Chemother. 2003 Jan;47(1):283-91.</citation>
          </article>
          <article>
            <ref-id>A11262</ref-id>
            <pubmed-id>12741835</pubmed-id>
            <citation>Fenn TD, Stamper GF, Morollo AA, Ringe D: A side reaction of alanine racemase: transamination of cycloserine. Biochemistry. 2003 May 20;42(19):5775-83.</citation>
          </article>
          <article>
            <ref-id>A11263</ref-id>
            <pubmed-id>15807525</pubmed-id>
            <citation>Fenn TD, Holyoak T, Stamper GF, Ringe D: Effect of a Y265F mutant on the transamination-based cycloserine inactivation of alanine racemase. Biochemistry. 2005 Apr 12;44(14):5317-27.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q9L888" source="Swiss-Prot">
        <name>Alanine racemase</name>
        <general-function>Pyridoxal phosphate binding</general-function>
        <specific-function>Catalyzes the interconversion of L-alanine and D-alanine.</specific-function>
        <gene-name>alr</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.52</theoretical-pi>
        <molecular-weight>41001.515</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1764">Mycobacterium avium</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF214487</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>6708455</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9L888</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALR_MYCAV</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5.1.1.1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001608|Alanine racemase
MAVTPISLTPGVLAEALVDLGAIEHNVRLLCEQARGAQVMAVVKADGYGHGAVQTARAAL
AAGAAELGVATVDEALALRAAGISAPVLAWLHPPGIDFRPALLAGVQIGLSSQRQLDELL
TAVRDTGRTATVTVKVDTGLNRNGVPPAQYPSMLTALRRAVAEQAIVPRGLMSHMVYADQ
PANPVNDVQAQRFTDMLAQAREQGVRFEVAHLSNSSATMSRPDLAFDMVRPGIAVYGLSP
VPELGDMGLVPAMTVKCTVALVKSIRAGESVSYGHTWTAQRDTNLALLPVGYADGIFRSL
GGRLQVSINGRRRPGVGRICMDQFVVDLGPGRPDVAEGDEAILFGPGSNGEPTAQDWADL
LGTIHYEVVTSPRGRITRTYREAHTVES</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0001607|1176 bp
ATGGCCGCCGTGGCCGTTACGCCGATATCCCTGACCCCGGGCGTCCTCGCCGAGGCGCTG
GTCGACCTGGGCGCCATCGAGCACAACGTGCGGCTGCTGTGCGAGCAGGCCCGCGGCGCG
CAGGTGATGGCCGTGGTCAAGGCCGACGGCTACGGCCACGGGGCCGTGCAGACGGCGCGT
GCCGCGCTGGCCGCCGGGGCCGCCGAGCTGGGCGTGGCCACCGTCGACGAGGCGCTGGCG
CTGCGCGCCGCGGGGATCAGCGCGCCGGTGCTGGCCTGGCTGCATCCGCCCGGCATCGAC
TTCCGGCCCGCGCTGCTGGCCGGCGTGCAGATCGGCCTGTCCTCGCAGCGCCAGCTCGAC
GAGCTGCTGACCGCGGTGCGCGACACCGGCCGGACCGCCACGGTCACCGTCAAGGTCGAC
ACCGGGCTGAACCGCAACGGCGTGCCGCCGGCGCAGTACCCGTCGATGCTGACCGCGCTG
CGCCGCGCCGTCGCCGAGCAGGCCATCGTGCCGCGCGGCCTGATGTCTCACATGGTGTAC
GCCGACCAACCCGCCAACCCGGTGAATGACGTTCAGGCGCAACGGTTCACCGACATGCTG
GCCCAGGCGCGCGAGCAGGGGGTGCGCTTCGAGGTGGCCCACCTGTCGAATTCGTCGGCC
ACCATGTCGCGTCCCGACCTGGCCTTCGACATGGTGCGCCCCGGTATCGCGGTGTACGGC
CTCAGCCCTGTCCCCGAGCTGGGCGACATGGGCCTGGTGCCCGCGATGACGGTGAAATGT
ACTGTGGCACTGGTGAAGTCGATACGTGCGGGGGAAAGCGTGTCATACGGACACACCTGG
ACGGCGCAGCGCGACACCAACCTGGCGCTGCTGCCGGTGGGCTACGCCGACGGCATCTTC
CGGTCGCTGGGCGGGCGGCTGCAGGTGTCGATCAACGGCCGGCGGCGGCCGGGCGTCGGC
CGGATCTGCATGGACCAGTTCGTCGTCGACCTGGGCCCGGGCCGCCCCGACGTGGCCGAG
GGCGACGAGGCGATCCTGTTCGGGCCGGGCAGCAACGGTGAACCCACCGCCCAGGATTGG
GCCGATCTGCTCGGCACTATCCACTACGAAGTGGTGACCAGCCCCCGCGGGCGGATCACC
AGGACCTACCGCGAGGCGCACACCGTTGAGTCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00842</identifier>
            <name>Ala_racemase_C</name>
          </pfam>
          <pfam>
            <identifier>PF01168</identifier>
            <name>Ala_racemase_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>alanine racemase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>D-alanine biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002151</id>
      <name>Aromatic-L-amino-acid decarboxylase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17699</ref-id>
            <pubmed-id>13885421</pubmed-id>
            <citation>DENGLER HJ, RAUCHS E, RUMMEL W: [On the inhibition of L-glutamic acid and L-DOPA decarboxylase by D-cycloserine and other isoxazolidones]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1962;243:366-81.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P20711" source="Swiss-Prot">
        <name>Aromatic-L-amino-acid decarboxylase</name>
        <general-function>Pyridoxal phosphate binding</general-function>
        <specific-function>Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.</specific-function>
        <gene-name>DDC</gene-name>
        <locus>7p11</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.21</theoretical-pi>
        <molecular-weight>53925.815</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2719</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DDC</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M76180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181521</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P20711</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DDC_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>4.1.1.28</synonym>
          <synonym>AADC</synonym>
          <synonym>DDC</synonym>
          <synonym>DOPA decarboxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037167|Aromatic-L-amino-acid decarboxylase
MNASEFRRRGKEMVDYMANYMEGIEGRQVYPDVEPGYLRPLIPAAAPQEPDTFEDIINDV
EKIIMPGVTHWHSPYFFAYFPTASSYPAMLADMLCGAIGCIGFSWAASPACTELETVMMD
WLGKMLELPKAFLNEKAGEGGGVIQGSASEATLVALLAARTKVIHRLQAASPELTQAAIM
EKLVAYSSDQAHSSVERAGLIGGVKLKAIPSDGNFAMRASALQEALERDKAAGLIPFFMV
ATLGTTTCCSFDNLLEVGPICNKEDIWLHVDAAYAGSAFICPEFRHLLNGVEFADSFNFN
PHKWLLVNFDCSAMWVKKRTDLTGAFRLDPTYLKHSHQDSGLITDYRHWQIPLGRRFRSL
KMWFVFRMYGVKGLQAYIRKHVQLSHEFESLVRQDPRFEICVEVILGLVCFRLKGSNKVN
EALLQRINSAKKIHLVPCHLRDKFVLRFAICSRTVESAHVQRAWEHIKELAADVLRAERE
</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011560|Aromatic-L-amino-acid decarboxylase (DDC)
ATGAACGCAAGTGAATTCCGAAGGAGAGGGAAGGAGATGGTGGATTACGTGGCCAACTAC
ATGGAAGGCATTGAGGGACGCCAGGTCTACCCTGACGTGGAGCCCGGGTACCTGCGGCCG
CTGATCCCTGCCGCTGCCCCTCAGGAGCCAGACACGTTTGAGGACATCATCAACGACGTT
GAGAAGATAATCATGCCTGGGGTGACGCACTGGCACAGCCCCTACTTCTTCGCCTACTTC
CCCACTGCCAGCTCGTACCCGGCCATGCTTGCGGACATGCTGTGCGGGGCCATTGGCTGC
ATCGGCTTCTCCTGGGCGGCAAGCCCAGCATGCACAGAGCTGGAGACTGTGATGATGGAC
TGGCTCGGGAAGATGCTGGAACTACCAAAGGCATTTTTGAATGAGAAAGCTGGAGAAGGG
GGAGGAGTGATCCAGGGAAGTGCCAGTGAAGCCACCCTGGTGGCCCTGCTGGCCGCTCGG
ACCAAAGTGATCCATCGGCTGCAGGCAGCGTCCCCAGAGCTCACACAGGCCGCTATCATG
GAGAAGCTGGTGGCTTACTCATCCGATCAGGCACACTCCTCAGTGGAAAGAGCTGGGTTA
ATTGGTGGAGTGAAATTAAAAGCCATCCCCTCAGATGGCAACTTCGCCATGCGTGCGTCT
GCCCTGCAGGAAGCCCTGGAGAGAGACAAAGCGGCTGGCCTGATTCCTTTCTTTATGGTT
GCCACCCTGGGGACCACAACATGCTGCTCCTTTGACAATCTCTTAGAAGTCGGTCCTATC
TGCAACAAGGAAGACATATGGCTGCACGTTGATGCAGCCTACGCAGGCAGTGCATTCATC
TGCCCTGAGTTCCGGCACCTTCTGAATGGAGTGGAGTTTGCAGATTCATTCAACTTTAAT
CCCCACAAATGGCTATTGGTGAATTTTGACTGTTCTGCCATGTGGGTGAAAAAGAGAACA
GACTTAACGGGAGCCTTTAGACTGGACCCCACTTACCTGAAGCACAGCCATCAGGATTCA
GGGCTTATCACTGACTACCGGCATTGGCAGATACCACTGGGCAGAAGATTTCGCTCTTTG
AAAATGTGGTTTGTATTTAGGATGTATGGAGTCAAAGGACTGCAGGCTTATATCCGCAAG
CATGTCCAGCTGTCCCATGAGTTTGAGTCACTGGTGCGCCAGGATCCCCGCTTTGAAATC
TGTGTGGAAGTCATTCTGGGGCTTGTCTGCTTTCGGCTAAAGGGTTCCAACAAAGTGAAT
GAAGCTCTTCTGCAAAGAATAAACAGTGCCAAAAAAATCCACTTGGTTCCATGTCACCTC
AGGGACAAGTTTGTCCTGCGCTTTGCCATCTGTTCTCGCACGGTGGAATCTGCCCATGTG
CAGCGGGCCTGGGAACACATCAAAGAGCTGGCGGCCGACGTGCTGCGAGCAGAGAGGGAG
TAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00282</identifier>
            <name>Pyridoxal_deC</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>amino acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatic-L-amino-acid decarboxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>L-dopa decarboxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>catecholamine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular amino acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular nitrogen compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to alkaloid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>indolalkylamine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>isoquinoline alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organismal aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phytoalexin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to pyrethroid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic vesicle amine transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="2">
      <id>BE0004704</id>
      <name>Proton-coupled amino acid transporter 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A17887</ref-id>
            <pubmed-id>15644866</pubmed-id>
            <citation>Kennedy DJ, Gatfield KM, Winpenny JP, Ganapathy V, Thwaites DT: Substrate specificity and functional characterisation of the H+/amino acid transporter rat PAT2 (Slc36a2). Br J Pharmacol. 2005 Jan;144(1):28-41.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q495M3" source="Swiss-Prot">
        <name>Proton-coupled amino acid transporter 2</name>
        <general-function>L-proline transmembrane transporter activity</general-function>
        <specific-function>Involved in a pH-dependent electrogenic neuronal transport and sequestration of small amino acids. Transports glycine and proline. Inhibited by sarcosine (By similarity).</specific-function>
        <gene-name>SLC36A2</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>59-79
82-102
149-169
198-218
223-243
265-285
297-317
350-370
380-400
405-425
438-458</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>53215.65</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:18762</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1162</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q495M3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S36A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PAT2</synonym>
          <synonym>Proton/amino acid transporter 2</synonym>
          <synonym>Solute carrier family 36 member 2</synonym>
          <synonym>TRAMD1</synonym>
          <synonym>Tramdorin-1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008555|Proton-coupled amino acid transporter 2
MSVTKSTEGPQGAVAIKLDLMSPPESAKKLENKDSTFLDESPSESAGLKKTKGITVFQAL
IHLVKGNMGTGILGLPLAVKNAGILMGPLSLLVMGFIACHCMHILVKCAQRFCKRLNKPF
MDYGDTVMHGLEANPNAWLQNHAHWGRHIVSFFLIITQLGFCCVYIVFLADNLKQVVEAV
NSTTNNCYSNETVILTPTMDSRLYMLSFLPFLVLLVLIRNLRILTIFSMLANISMLVSLV
IIIQYITQEIPDPSRLPLVASWKTYPLFFGTAIFSFESIGVVLPLENKMKNARHFPAILS
LGMSIVTSLYIGMAALGYLRFGDDIKASISLNLPNCWLYQSVKLLYIAGILCTYALQFYV
PAEIIIPFAISRVSTRWALPLDLSIRLVMVCLTCLLAILIPRLDLVISLVGSVSGTALAL
IIPPLLEVTTFYSEGMSPLTIFKDALISILGFVGFVVGTYQALDELLKSEDSHPFSNSTT
FVR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013270|Proton-coupled amino acid transporter 2 (SLC36A2)
ATGTCTGTGACAAAAAGTACTGAGGGTCCCCAGGGAGCCGTTGCCATCAAATTGGACCTT
ATGTCGCCTCCTGAAAGTGCCAAGAAGTTGGAGAACAAGGACTCTACATTCTTGGATGAA
AGTCCTTCAGAGTCAGCAGGCTTGAAGAAGACCAAGGGCATAACAGTGTTCCAGGCCTTG
ATTCACCTGGTGAAAGGCAACATGGGCACAGGGATCCTGGGACTACCCCTCGCTGTGAAG
AACGCGGGCATCCTGATGGGCCCACTCAGTCTGCTGGTGATGGGCTTCATTGCCTGCCAC
TGTATGCACATCCTGGTCAAGTGTGCCCAGCGCTTCTGTAAGAGGCTTAACAAGCCCTTT
ATGGACTATGGGGACACGGTGATGCATGGACTAGAAGCCAACCCCAACGCCTGGCTCCAG
AATCACGCTCACTGGGGAAGGCATATCGTGAGCTTCTTCCTTATTATCACCCAACTTGGC
TTCTGCTGTGTGTACATTGTGTTTTTGGCTGATAATTTAAAACAGGTAGTGGAAGCTGTT
AATAGCACAACCAACAACTGCTATTCCAATGAGACGGTGATTCTGACCCCCACCATGGAC
TCGCGACTCTACATGCTCTCCTTCCTGCCCTTCCTGGTGCTGCTGGTCCTCATCCGGAAC
CTCAGGATCTTGACCATCTTCTCCATGCTGGCCAACATCAGCATGCTGGTCAGCTTGGTC
ATCATCATACAGTACATTACCCAGGAAATCCCAGACCCCAGCCGGTTGCCACTGGTAGCA
AGCTGGAAGACCTACCCTCTCTTCTTCGGAACAGCCATTTTTTCTTTTGAAAGCATTGGT
GTGGTTCTGCCTCTGGAAAACAAGATGAAGAATGCCCGCCACTTCCCAGCCATCCTGTCT
TTGGGAATGTCCATCGTCACTTCCCTATACATTGGCATGGCGGCTCTGGGCTACCTGCGG
TTTGGAGATGACATCAAGGCCAGCATAAGCCTTAACCTGCCTAACTGCTGGCTGTACCAG
TCTGTCAAGCTTCTCTACATTGCCGGCATCCTGTGCACCTATGCCCTGCAGTTCTACGTC
CCTGCAGAAATCATCATCCCCTTTGCCATCTCCCGGGTGTCAACACGCTGGGCACTGCCT
CTGGATCTGTCCATTCGCCTCGTCATGGTCTGCCTGACATGCCTCCTGGCCATCCTCATC
CCCCGCCTGGACCTGGTCATCTCCCTGGTGGGCTCCGTGAGTGGCACCGCCCTGGCCCTC
ATCATCCCACCGCTCCTGGAGGTCACCACGTTCTACTCAGAGGGCATGAGCCCCCTCACC
ATCTTCAAGGACGCCCTGATCAGCATCCTGGGCTTCGTGGGCTTTGTGGTGGGGACCTAC
CAGGCCCTGGACGAGCTGCTCAAGTCAGAAGACTCTCACCCCTTTTCCAACTCCACCACT
TTTGTTCGGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01490</identifier>
            <name>Aa_trans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vacuolar membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glycine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hydrogen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hydrogen ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>L-alanine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>L-proline transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>amino acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>L-alanine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proline transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>